Incomplete POEMS syndrome with multicentric Castleman's disease and amyloidosis
DOI:
https://doi.org/10.23938/ASSN.0041Keywords:
POEMS syndrome. Castleman's disease. Amyloidosis.Abstract
Castleman's disease (CD) is an atypical lymphoproliferative disorder of unknown cause, characterized by non-clonal nodal hyperplastic growth. Two forms of clinical presentation are currently recognized, one localized and the other multicentric, and four histopathologic variants. It is characterized by generalized lymphadenopathy, hepatosplenomegaly, fever and night sweats.
CD may present severe pancytopenia, multi-organ failure, lymphoma evolution and it can sometimes be associated with paraneoplastic syndromes such as POEMS syndrome. Associations of these two entities have been widely described in the current literature, although its less common association with amyloidosis is described as isolated clinical cases. We report a case with this triple association: EC, POEMS and amyloidosis.
Downloads
References
DISPENZIERI A. POEMS syndrome update on diagnosis, risk-stratification, and management. Am J Hematol 2014; 89: 214-223.
GRACIA-RAMOS AE, CRUZ-DOMÍNGUEZ M DEL P, VERA-LASTRA OL. Multicentric hyaline vascular Castleman's disease: a POEMS type variant. Rev Med Inst Mex Seguro Soc 2013; 51: 464-467.
NICOLI P, FAMILIARI U, BOSA M, ALLICE T, METE F, MOROTTI A, et al. HHV8-positive, HIV-negative multicentric Castleman’s disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma. Int J Hematol 2009; 90: 392-396
CARO-CUENCA MT, ORTEGA-SALAS R, ESPINOSA-HERNÁNDEZ M. RENAL AA amyloidosis in a Castleman's disease patient. Nefrologia 2012; 32:699-700.
BESTARD MATAMOROS O, POVEDA MONJE R, IBERNON VILARÓ M, CARRERA PLANS M,. GRINYÓ BOIRA JM, Amiloidosis secundaria (AA) asociada a tumoraciones benignas. Nefrologia 2008; 28: 93-98.
VERBRUGGHE W, MAES BD, KNOCKAERT DC. Localised plasma-cell type Castleman's disease and AA-amyloidosis cured by resection. A case report and review of the literature. Acta Clin Belg 2005; 60:22-27.
IBRAHIM K, MAGHFOOR I, ELGHAZALY A, BAKSHI N, MOHAMED S, ALJURF M. Successful treatment of steroid refractory autoimmune thrombocytopenia associated with Castleman disease with anti-CD-20 antibody (rituximab). Hematol Oncol Stem Cell Ther 2011; 4: 100-102.
IIJIMA T, HOSHINO J, SUWABE T, SUMIDA K, MISE K, KAWADA M, et al. Tocilizumab for AA Amyloidosis after treatment of multicentric Castleman disease with steroids, chemotherapy and rituximab for over 20 years. Intern Med 2015; 54:3215-3219.
GADUPUTI V, TARIQ H, BADIPATLA K, IHIMOYAN A. Systemic reactive amyloidosis associated with Castleman's disease. Case Rep Gastroenterol 2013; 7:476-481.
PAYDAS S, PAYDAS S, ERGIN M. Colchicine therapy in amyloidosis related with plasmacytic Castleman disease presenting with nephrotic syndrome. Saudi J Kidney Dis Transpl 2015; 26:992-995.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
